Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis.

OBJECTIVE To examine the concentration of the soluble form of the Fas molecule (sFas) in the serum and synovial fluid of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). METHODS The concentration of sFas in the serum of 15 normal subjects and in the synovial fluid and serum of 45 RA patients and 13 OA patients was determined. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and the level of several cytokines in serum and synovial fluid were also determined. RESULTS The synovial fluid concentration of sFas was higher in RA than in OA patients (P < 0.005). The synovial fluid level of sFas correlated weakly with serum levels of CRP (r = 0.541), the ESR (r = 0.499), and with synovial fluid levels of interleukin-2 (IL-2) receptor (r = 0.544), IL-6 (r = -0.529), and intercellular adhesion molecule 1 (r = 0.514). Reverse transcription-polymerase chain reaction analysis revealed that synovial cells and infiltrating mononuclear cells expressed sFas messenger RNA in RA patients. CONCLUSION Our data suggest that accumulation of sFas in the joint cavity of RA patients may inhibit apoptosis and exacerbate the inflammatory process.

[1]  T. Sumida,et al.  Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis. , 1996, International immunology.

[2]  H. Inoue,et al.  Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. , 1996, Clinical immunology and immunopathology.

[3]  T. Sumida,et al.  Novel mechanisms of selective apoptosis in synovial T cells of patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[4]  N. Goel,et al.  Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. , 1995, Arthritis and rheumatism.

[5]  P. Krammer,et al.  Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[6]  G. Firestein,et al.  Apoptosis in rheumatoid arthritis synovium. , 1995, The Journal of clinical investigation.

[7]  C. Ware,et al.  Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? , 1995, Cancer letters.

[8]  M. Weller,et al.  Fas/APO-1 gene transfer for human malignant glioma. , 1995, Cancer research.

[9]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[10]  T. Nakajima,et al.  Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. , 1995, Arthritis and rheumatism.

[11]  R. Testi,et al.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase , 1994, The Journal of experimental medicine.

[12]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[13]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[14]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[15]  T. Nakajima,et al.  Detection of human T cell lymphotropic virus type I proviral DNA and its gene expression in synovial cells in chronic inflammatory arthropathy. , 1991, The Journal of clinical investigation.

[16]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[17]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[18]  H. Yamanaka,et al.  Spontaneous production of an interleukin 1-like factor by cloned rheumatoid synovial cells in long-term culture. , 1987, The Journal of clinical investigation.